Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

被引：3

作者：

Shah, Nirav N. ^{[1
]}

Zinzani, Pier Luigi ^{[2
]}

Wang, Michael L. ^{[3
]}

Nasta, Sunita D. ^{[4
]}

Lech-Maranda, Ewa ^{[5
]}

Ogawa, Yoshiaki ^{[6
]}

Fakhri, Bita ^{[7
]}

Kuss, Bryone ^{[8
,9
]}

Miyashita, Kaname ^{[10
]}

Patel, Krish ^{[11
]}

Coombs, Catherine C. ^{[12
]}

Ma, Shuo ^{[13
]}

Patel, Manish ^{[14
]}

Barve, Minal A. ^{[15
]}

Tessoulin, Benoit ^{[16
,17
]}

Stathis, Anastasios ^{[18
]}

Kim, Won Seog ^{[19
]}

Ennishi, Daisuke

Hashimoto, Daigo ^{[20
,21
]}

Kojima, Kensuke ^{[22
]}

Zelenetz, Andrew D. ^{[23
]}

Cohen, Jonathon B. ^{[24
]}

Vose, Julie M. ^{[25
]}

Maddocks, Kami J. ^{[26
]}

Munir, Talha ^{[27
]}

Sun, Fangfang ^{[28
]}

Bian, Faith ^{[28
]}

Tsai, Donald E. ^{[29
]}

Abada, Paolo ^{[29
]}

Cheah, Chan Y. ^{[30
,31
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI USA

[2] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[3] Texas MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[5] Inst Hematol & Transfus Med, Warsaw, Poland

[6] Tokai Univ, Sch Med, Hiratsuka, Kanagawa, Japan

[7] Stanford Univ, Sch Med, Stanford, CA USA

[8] Flinders Med Ctr, Bedford Pk, Australia

[9] Flinders Univ S Australia, Bedford Pk, Australia

[10] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan

[11] Swedish Canc Inst, Seattle, WA USA

[12] Univ Calif Irvine, Irvine, CA USA

[13] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[14] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[15] Mary Crowley Canc Res, Dallas, TX USA

[16] Nantes Univ, Sch Med, Nantes, France

[17] Univ Hosp Nantes, Nantes, France

[18] Oncol Inst Southern Switzerland, Bellinzona, Switzerland

[19] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[20] Okayama Univ Hosp, Okayama, Japan

[21] Hokkaido Univ Hosp, Sapporo, Japan

[22] Kochi Med Sch Hosp, Nankoku, Japan

[23] Mem Sloan Kettering Canc Ctr, New York, NY USA

[24] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[25] Univ Nebraska Med Ctr, Omaha, NE USA

[26] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[27] St James Univ Hosp, Dept Haematol, Leeds, England

[28] Eli Lilly & Co, Indianapolis, IN USA

[29] Loxo Lilly, Indianapolis, IN USA

[30] Linear Clin Res, Perth, Australia

[31] Sir Charles Gairdner Hosp, Perth, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181309

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：9

共 50 条

[31] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study
Eyre, Toby
Shah, Nirav N.
Alencar, Alvaro
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine C.
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal A.
Ghia, Paolo
Yin, Ming
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 142 - 143
[32] LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Mato, Anthony
Cheah, Chan Yoon
BLOOD, 2020, 136
[33] Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, Anthony R.
Shah, Nirav N.
Jurczak, Wojciech
Cheah, Chan Y.
Pagel, John M.
Woyach, Jennifer A.
Fakhri, Bita
Eyre, Toby A.
Lamanna, Nicole
Patel, Manish R.
Alencar, Alvaro
Lech-Maranda, Ewa
Wierda, William G.
Coombs, Catherine C.
Gerson, James N.
Ghia, Paolo
Le Gouill, Steven
Lewis, David John
Sundaram, Suchitra
Cohen, Jonathon B.
Flinn, Ian W.
Tam, Constantine S.
Barve, Minal A.
Kuss, Bryone
Taylor, Justin
Abdel-Wahab, Omar
Schuster, Stephen J.
Palomba, M. Lia
Lewis, Katharine L.
Roeker, Lindsey E.
Davids, Matthew S.
Tan, Xuan Ni
Fenske, Timothy S.
Wallin, Johan
Tsai, Donald E.
Ku, Nora C.
Zhu, Edward
Chen, Jessica
Yin, Ming
Nair, Binoj
Ebata, Kevin
Marella, Narasimha
Brown, Jennifer R.
Wang, Michael
LANCET, 2021, 397 (10277): : 892 - 901
[34] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 13 - 14
[35] Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results
Cohen, Jonathon B.
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fahkri, Bita
Jurczak, Wojciech
Tan, Xuan N.
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian
Lewis, David J.
Le Gouill, Stephen
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S378 - S379
[36] Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
Shah, Nirav N.
Wang, Michael L.
Brown, Jennifer R.
Patel, Krish
Woyach, Jennifer A.
Wierda, William G.
Ujjani, Chaitra S.
Eyre, Toby A.
Zinzani, Pier Luigi
Alencar, Alvaro J.
Gastinne, Thomas
Ghia, Paolo
Lamanna, Nicole
Hoffmann, Marc
Patel, Manish R.
Flinn, Ian W.
Gerson, James N.
Ma, Shuo
Coombs, Catherine C.
Cheah, Chan Y.
Lech-Maranda, Ewa
Fakhri, Bita
Kim, Won-Seog
Barve, Minal A.
Cohen, Jonathon B.
Jurczak, Wojciech
Munir, Talha
Thompson, Meghan C.
Roeker, Lindsey E.
Bao, Katherine
Cangemi, Nicholas A.
Kherani, Jennifer F.
Walgren, Richard A.
Han, Hongmei
Ruppert, Amy S.
Mato, Anthony R.
BLOOD, 2022, 140 : 4127 - 4132
[37] Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Izutsu, Koji
Ma, Shuo
Flinn, Ian
Alencar, Alvaro J.
Lewis, David
Patel, Krish
Maddocks, Kami
Wang, Yucai
Munir, Talha
Zelenetz, Andrew D.
Balbas, Minna
Tsai, Donald E.
Wang, Chunxiao
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S459 - S459
[38] Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from BRUIN
Munir, Talha
Mato, Anthony R.
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Patel, Krish
Eyre, Toby A.
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John F.
Shah, Nirav N.
Coombs, Catherine C.
Ujjani, Chaitra S.
Patel, Manish R.
Fakhri, Bita
Cheah, Chan Y.
Alencar, Alvaro J.
Cohen, Jonathon B.
Gerson, James N.
Flinn, Ian W.
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Hernandez-Ilizaliturri, Francisco
Zinzani, Pier Luigi
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Denise
Tsai, Donald E.
Wierda, William G.
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 110 - 111
[39] Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I/II BRUIN Study
Brown, Jennifer
Desikan, Sai Prasad
Nguyen, Bastien
Won, Helen
Tantawy, Shady I.
McNeely, Samuel C.
Marella, Narasimha
Ebata, Kevin
Woyach, Jennifer
Patel, Krish
Tam, Constantine S.
Eyre, Toby A.
Cheah, Chan Y.
Shah, Nirav
Ghia, Paolo
Jurczak, Wojciech
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Denise
Mato, Anthony
Gandhi, Varsha
Wierda, William
LEUKEMIA & LYMPHOMA, 2023, 64 : S25 - S26
[40] Phase 1 dose escalation study of MH048, a novel and non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies.
Cao, Guoqing
Jin, Zhengming
Li, Yuhua
Zhang, Liling
Shi, Junwei
Jin, Jie
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →